In The News

March 23, 2021
Abstract Emerging retrospective and prospective studies indicate that immune checkpoint inhibitors (ICIs) can be safe and effective cancer treatments among people living with human immunodeficiency…
March 19, 2021
The global “COVID-19 Diagnostics ” Market is projected to reach USD 11.40 billion by 2027, exhibiting a CAGR of 7.9% during the forecast period. Uncontrolled spread of the coronavirus worldwide will…
March 19, 2021
Here we go again: Senator Rand Paul on Thursday faced master of reality Fauci once again. However, for some weird reason, Rand Paul failed to ask Bill Gates’ dog (you can find many references to…
March 18, 2021
Joe Biden’s pick to head the Food and Drug Administration was supposed to be an easy one. But two months into his presidency, the search for a commissioner to run a health agency critical to the…
March 17, 2021
ABSTRACT BACKGROUND: The COVID-19 pandemic remains a significant global threat. However, despite urgent need, there remains uncertainty surrounding best practices for pharmaceutical interventions to…
March 11, 2021
Executive Summary Oncologic Drugs Advisory Committee will meet for three days in April to consider whether indications for Tecentriq, Keytruda and Opdivo should remain on label despite failure to…
March 11, 2021
Six indications for immune checkpoint inhibitors (ICIs) granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency…
March 10, 2021
ASCO and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials…
March 8, 2021
Executive Summary A common toxicity of advanced IO therapies, cytokine release syndrome needs to be better characterized as part of the groundwork for future development of the field, according to…
March 4, 2021
Merck & Co is withdrawing the US indication for pembrolizumab (Keytruda) for metastatic small cell lung cancer (SCLC) in patients with disease progression on or after platinum-based chemotherapy…